Hearing aids showed no clear effect on NfL in humans (untreated hearing loss without substantial cognitive impairment) (difference: -0.159; 95 %CI: -0.348, 0.029).
“After six months of hearing aid use, we re-evaluated the MMSE and SRT scores and serum biomarkers levels in the ARHL group: we recorded significant improvements both in cognitive and word recognition tests and in biomarker values.”
“NFL and GFAP levels were statistically lower in the study group at the end of the study than before the study.”
Human trialRelapsing-remitting multiple sclerosis; aerobic exercise plus home exercises, compared with baselineserum3 times per week at 60–70% of maximal aerobic capacity8 weeks
Vitamin K is linked with lower NfL in humans (third vitamin K intake tertile vs first tertile) (β = -0.16 [95% confidence interval -0.29 to -0.02]; p = 0.023).
“Individuals in the third vitamin K intake tertile exhibited lower serum NfL levels than those in the first tertile (regression coefficient, β = -0.16 [95% confidence interval -0.29 to -0.02]; p = 0.023).”
Humansthird vitamin K intake tertile vs first tertile
Cholecalciferol decreases NfL in humans Among Black participants (-16.2% (95% CI: −30.5% to 1.1%)).
“Among Black participants, there was a mean 16.2% reduction in NfL levels (95% CI: −30.5% to 1.1%; p‐interaction = 0.06; Table ) comparing the vitamin D3 and placebo groups”
Endurance exercise decreases NfL in rats (WKY72 rat model of tauopathy) (3.8-fold increase in trained animals versus 8.9-fold increase in sedentary animals).
“moderate-intensity endurance exercise attenuates plasma level of NfL in tauopathic rats”
AnimalsWKY72 rat model of tauopathymoderate-intensity treadmill trainingplasma30 min/day, 5 days/week
Mindfulness showed no clear effect on NfL in humans within-arm from baseline to follow-up (V1 to V3) (-3.0%).
“Within the CMBAS arm, there was no significant change in log NfL from V1 to V2 (estimated change [95 % confidence interval]: −0.05 [−0.12 to 0.02]), or V1 to V3 (−0.03 [−0.10 to 0.04]).”
Human trialwithin-arm from baseline to follow-up (V1 to V3)8-week arms and a 6-month follow-up
“CSF NfL was also lower (paired t‐test p = 0.046), and plasma NfL showed a similar trend (paired t‐test p = 0.16), as did plasma pTau217 (paired t‐test p = 0.084).”
Multidisciplinary intensive outpatient rehabilitation program
↓downin humans1
1 study
Multidisciplinary intensive outpatient rehabilitation program decreases NfL in humans (Parkinson's disease; compared with a home-based self-managed intervention).
“NFL levels significantly decreased in the EXP group at both time points, whereas an increase was observed at follow-up in the CTRL group.”
Human trialParkinson's disease; compared with a home-based self-managed interventionplasmapost-treatment and 3-month follow-upn = 40
Vaccinium corymbosum showed no clear effect on NfL in humans (cognitively healthy) (p for interaction 0.58).
“or serum NFL [i.e., corresponding values were 26.2 (18.2-34.1) and 25.0 (17.1-33.0) pg/mL in the placebo group and 26.6 (18.2-35.0) and 28.0 (19.5-36.5) pg/mL in the blueberry group, p for interaction 0.58]”
Human trialcognitively healthypowder20 g/d24 weeksn = 57
NfL is linked with cognitive function in humans (Indirect effect −0.0046 (95% CI −0.0089 to −0.0014); p=0.004; 18.05% mediated).
“Mediation analyses identified significant indirect pathways through NfL linking depressive symptoms with poorer subsequent cognitive performance”
HumansStatistical mediation of the prospective association between baseline depressive symptoms and subsequent cognitionmean interval 6.34 yearsn = 921
NfL is linked with worse cognitive function in humans (linear β coefficients: -0.022 to -0.300).
“Higher plasma levels of p ‐tau181, GFAP and NfL were associated with a greater decline in global cognitive function, verbal fluency, episodic memory and psychomotor speed (linear β coefficients: ‐0.022 to ‐0.300).”
NfL is linked with Alzheimer's disease in humans (Indirect effect 0.0033 (95% CI 0.0000 to 0.0073); p=0.046; 16.15% mediated).
“NfL also mediated the prospective association between depressive symptoms and incident AD”
HumansStatistical mediation of the prospective association between depressive symptoms and incident Alzheimer's disease; significance attenuated in fully adjusted modelsn = 445
Alzheimer's & dementia : the journal of the Alzheimer's Association·
NfL is linked with dementia in humans (association between ILF and incident dementia) (7.3% mediated proportion).
“In mediation models, higher NfL and p Tau181 accounted for modest proportions of the observed association between ILF and incident dementia, with estimated mediated proportions of 7.3% for NfL and 4.9% for p Tau181.”
Humansassociation between ILF and incident dementiaplasman = 4,072
NfL is linked with worse physical function in humans (cognitively unimpaired).
“Higher neurofilament light was associated with worse expanded short physical performance battery, slower 4 m gait speed, and slower 400 m gait speed in adjusted models.”
The journals of gerontology. Series A, Biological sciences and medical sciences·
NfL is linked with worse physical function in humans (0.15 units (95% CI 0.21, 0.08) faster annual decline).
“In participants with 2-fold higher concentrations of serum NfL, the annual rate of decline in physical functioning increased by 0.15 units (95% CI 0.21, 0.08).”
Age is linked with higher NfL in humans (Spearman's ρ=0.721, c<0.001).
“NfL concentrations increased markedly with age (Spearman's ρ=0.721, c<0.001), with median values rising from 8.45pg/mL in individuals aged 18-34years to 23.4pg/mL in those aged ≥69years.”
Obesity is linked with lower NfL in humans (obesity compared with normal weight) (median 1.72 pg/mL lower with obesity compared with normal weight (BMI 30 vs 20)).
“Median NfL and GFAP concentrations were 1.72 (1.72-1.72) pg/mL and 12.6 (12.6-12.6) pg/mL lower, respectively, in participants with obesity compared with those with normal weight”
NfL predicts cognitive function in humans (Down syndrome, controlling for age) (posterior distributions ≥ 94.75%).
“Protein baseline levels were associated with cognitive decline over time while controlling for age in the whole cohort (all posterior distributions ≥ 94.75%).”
HumansDown syndrome, controlling for ageplasman = 59
NfL predicts cognitive function in humans (non-ε4 carriers) (β = -0.025 [95% CI, -0.031 to -0.020]).
“higher levels of NfL and GFAP were associated with faster cognitive decline only in non-ε4 carriers (β = -0.025 [95% CI, -0.031 to -0.020]) and -0.017 [95% CI, -0.022 to -0.012], respectively)”
NfL is associated with cognitive function in humans (Cluster A subgroup of severe mental disorders) (r = -0.486, p < 0.01).
“In this subgroup, NfL levels were significantly and negatively correlated with orientation ( r = −0.452, p < 0.05), attention/calculation ( r = −0.435, p < 0.05), memory ( r = −0.352, p < 0.05), and comprehension ( r = −0.486, p < 0.01).”
HumansCluster A subgroup of severe mental disordersblood
Age is associated with NfL in humans (r = 0.81 (95% CI 0.78-0.83), p < 0.0001).
“The spearman r of the association with age was 0.81 (95% CI 0.78-0.83), p < 0.0001 and 0.82 (95% CI 0.79-0.85), p < 0.0001 for serum and CSF NfL, respectively.”
medRxiv : the preprint server for health sciences·Preprint
NfL predicts mortality in persons with chronic coronary syndrome (HR 1.36 (95% CI 1.10-1.68)).
“Participants with higher NfL levels had increased rates of all-cause and cardiovascular mortality (Hazard ratio per increase by one standard deviation (95 % confidence interval): all-cause mortality: 1.36 (1.10-1.68)”
Humansin persons with chronic coronary syndromen = 379
NfL predicts dementia in humans among individuals with impaired kidney function (HR, 3.85 [95% CI 1.87-7.95]).
“The relationship between increased (high vs low) NfL and dementia was stronger among individuals with impaired (vs preserved) kidney function (HR, 3.85 [95% CI 1.87-7.95] vs HR, 1.84 [95% CI 1.34-2.53], respectively).”
Humansamong individuals with impaired kidney functionmean 8.3 yearsn = 2,279
NfL is associated with Alzheimer's disease in humans (Baseline concentration standardized as a covariate-adjusted z-score) (HR 1.31; 95% CI 1.22–1.41).
“AD (HR 1.31; 95% CI, 1.22-1.41, p < 0.001)”
HumansBaseline concentration standardized as a covariate-adjusted z-scoreplasma
NfL raises the risk of Alzheimer's disease in humans (effect size 1.60).
“plasma neurofilament light chain (1.60, I2 = 37%), and C-reactive protein (1.30, I2 = 25%) are genetic biomarkers that show significant predictive values.”
NfL is associated with cognitive impairment in humans (HR 1.34, 95% CI 1.06–1.69).
“both NfL (HR = 1.34, 95% CI 1.06-1.69, P = 0.014) and p-tau217 (HR = 1.47, 95% CI 1.14-1.89, P = 0.003) remained associated with incident cognitive impairment.”
HumansCognitively unimpaired patients with obstructive sleep apnea; jointly modeled with p-tau217PlasmaMedian follow-up of 4.18 yearsn = 286
NfL is linked with a higher risk of cognitive impairment in diabetic individuals (OR 1.04, 95% CI 1.010-1.071, P = .031).
“each unit increase in serum NfL was associated with increased odds of cognitive impairment (odds ratio 1.04, 95% confidence interval: 1.010-1.071, P = .031)”
NfL predicts sarcopenia in humans (COPD) (AUC = 0.806, p < 0.05).
“Plasma NfL also demonstrated an acceptable accuracy in diagnosing sarcopenia in controls (AUC = 0.757, p < 0.05) and COPD (AUC = 0.806, p < 0.05) patients.”
NfL is associated with sarcopenia in humans (P < 0.001).
“Neurofilament light chain levels were associated with grip strength and SMI (P = 0.005 and P = 0.045, respectively) and were significantly elevated in sarcopenic individuals, compared with non-sarcopenic participants (P < 0.001).”
Alzheimer's & dementia : the journal of the Alzheimer's Association·
NfL is associated with white matter hyperintensities in humans (non-demented) (β = 0.0798, SE = 0.0436, p = 0.0344).
“A positive association was also observed between NfL levels and WMH level (β = 0.0798, SE = 0.0436, p = 0.0344), even after adjusting for covariates.”
NfL is associated with white matter hyperintensities in humans.
“All measures (VRFs, gait, behavioral, plasma GFAP, plasma NfL) were associated with white matter hyperintensities (WMHs) but mainly in intermediate and high age strata.”
NfL is associated with delirium severity in humans (preoperative NfL, per one-standard-deviation increase) (0.32-point increase in CAM-S (95% CI 0.14-0.50)).
“A one-standard-deviation increase in preoperative NfL was associated with a 0.32-point increase in CAM-S (95% confidence interval [0.14-0.50], p = 0.001).”
Human trialpreoperative NfL, per one-standard-deviation increasepeak within 3 days after surgeryn = 355
A blood marker of nerve-fiber damage statistically accounted for 18.05% of the link between depressive symptoms and poorer later cognitive performance.A blood marker of nerve-fiber damage statistically accounted for 18.05% of the link between depressive symptoms and poorer later cognitive performance.